Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines
Akbar K Waljee1,2, Kay Sauder2, Anand Patel3
1Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.
Journal of Crohn'S & Colitis
|March 24, 2017
Summary
Machine learning algorithms can identify patients with inflammatory bowel disease (IBD) in remission on thiopurine therapy, leading to fewer clinical events. This approach improves upon traditional metabolite monitoring for predicting treatment success and patient outcomes.
Area of Science:
- * Computational biology and bioinformatics
- * Clinical data science
- * Precision medicine in gastroenterology
Background:
- * Thiopurine therapy is crucial for inflammatory bowel disease (IBD) management but optimizing it is challenging.
- * Current methods using 6-thioguanine nucleotide (6-TGN) metabolites have limitations in predicting objective remission (OR).
- * Big data analytics and machine learning algorithms (MLAs) offer potential for improved clinical decision-making.
Purpose of the Study:
- * To develop MLAs using laboratory values and age to identify IBD patients in objective remission on thiopurines.
- * To assess if achieving algorithm-predicted objective remission (APR) reduces clinical events.
- * To compare MLA performance against traditional 6-TGN metabolite monitoring.
Main Methods:
- * Retrospective analysis of 1080 IBD patients on thiopurine therapy.
- * Development of MLAs to predict objective remission, non-adherence, and 6-methylmercaptopurine (6-MMP) shunting.
- * Evaluation of algorithm performance using area under the receiver operating characteristic curve (AuROC).
- * Measurement of clinical events including steroid prescriptions, hospitalizations, and surgeries.
Main Results:
- * MLAs achieved an AuROC of 0.79 for predicting remission, outperforming 6-TGN (AuROC 0.49).
- * Patients with sustained algorithm-predicted remission (APR) experienced significantly fewer clinical events per year (1.08 vs. 3.95, p < 1x10⁻⁵).
- * APR was associated with significant reductions in steroid prescriptions/year (-1.63) and hospitalizations/year (-1.05).
Conclusions:
- * A machine learning algorithm effectively identifies IBD patients in objective remission on thiopurines.
- * Algorithm-predicted objective remission is linked to substantial clinical benefits, including reduced steroid use and hospitalizations.
- * This data-driven approach holds promise for optimizing thiopurine therapy and improving patient outcomes in IBD.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
616
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
616
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
47
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
47
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
670
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
670
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
582
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
582
01:29Therapeutic Drug Monitoring: Affecting Factors
299
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
299